Posts Tagged ‘Op-ed’
Colorado’s Canadian Rx import plan fuels counterfeit Ozempic dangers
Executive Director Shabbir Safdar’s editorial ran on May 15, 2024 in Colorado Politics
[...]PSM board president, pharmacist explains why foreign drug importation can’t deliver.
In this editorial, which appeared in the Corpus Christi Caller on June 30, 2023, Doctor of Pharmacy Kenneth McCall shares his negative experience with imported medicines.
[...]The Hollow Promise of Drug Importation Proposals
Tom Kubic—an FBI veteran, former president and CEO of the Pharmaceutical Security Institute, and president of PSM’s governing board—has the experience to know that the risks of drug importation are “unacceptably high” and the potential rewards are “virtually nil.”
[...]Head of Missouri Pharmacy Association Calls for Rider-Free PDUFA Passage
One proposed amendment which could delay, or derail prompt passage, would allow importation of drugs from other countries which have not been inspected or approved by the FDA. Because the FDA ensures strict oversight of purity and effectiveness of the drugs in our supply chain, this proposal is dangerous. Everyday customs officials are finding counterfeit drugs which are laced with dangerous ingredients like fentanyl, mercury, lead, or other toxins.
[...]Former Florida Congresswoman Calls Drug Importation a ‘False Promise’.
So, what does all of this have to do with importing drugs from a friendly nation like Canada? The simple, inarguable fact is that, once we open up our drug supply, we can no longer ensure the safety of the products in it.
[...]Director of Health and Science Policy at Citizens Against Government Waste Calls Drug Importation Dangerous
Instead of wasting time and money on dangerous and faulty importation proposals, Congress should encourage the FDA to speed up the drug approval process and reduce the cost of program and application fees for future drug development. In 2022, the application fee for a human drug application will cost $1.6 million for drugs that don’t require clinical data and $3.1 million for medicines that do need clinical data.
[...]Connecticut Bioscience Growth Council ED explains why drug importation is “unworkable.”
In this February 24, 2022 editorial published on the Connecticut Business & Industry Association’s website, Paul Pescatello reviews the practical reasons that mean that importing drugs from Canada will not lower prescription drug prices. Pescatello is the executive director of CBIA’s Bioscience Growth Council and chair of We Work for Health Connecticut.
[...]Counterfeit HIV drug underscores risks of a weaker drug supply chain, advocate warns.
ADAP Advocacy Association CEO Brandon M. Macsata wrote this editorial, which appeared on the AIDS Drug Assistance Program’s website on April 1, 2021.
The Association first warned constituents that counterfeit Symtuza had been distributed to three U.S. pharmacies in December 2020, when Janssen issued an alert.
[...]Canada’s Actions a Death-Knell for Drug Importation in Florida
This editorial by the Sun Sentinel Editorial Board was published in The Sun Sentinel on December 9, 2020. The Editorial Board consists of Editorial Page Editor Rosemary O’Hara, Dan Sweeney, Steve Bousquet and Editor-in-Chief Julie Anderson. There Go Those Cheaper Drugs. Remember Florida’s plan to save money by importing prescription drugs in bulk from Canada?…
[...]Canadian writer applauds country’s effort to protect its drug supply
This editorial by Joyce Nelson appeared in Counter Punch on December 4, 2020. Nelson is a researcher and writer whose work appears in a wide range of magazines, newspapers and websites.
[...]